Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Postoperative Fistula
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine whether teduglutide is safe and feasible to be given for the treatment of enterocutaneous fistula (ECF). We hypothesize that the drug will be well-tolerated and will improve the volume of daily ECF output as well as improve the functional quality of life.

Provided treatments

  • Drug: teduglutide
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02889393. The sponsor of the trial is Daniel Dante Yeh and it is looking for 10 volunteers for the current phase.
Official trial title:
Teduglutide for Treatment of Enterocutaneous Fistula (ECF) - a Pilot Study to Demonstrate Safety and Feasibility